Findings may help with decision-making in this high-risk patient population.
ATS 2021, News
Patients with normal adrenal function are largely able to eliminate the use of oral corticosteroids or achieve a daily dose of 5 mg or less.
AAAAI 2021, News
Patients with asthma who depend on oral corticosteroids (OCS) may be able to reduce the dependence or eliminate the use of OCS altogether with benralizumab.
To what extent are patients with uncontrolled asthma switched to biologics due to poor treatment adherence vs lack of maintenance therapy efficacy?
CHEST 2021, News
NAVIGATOR trial results presented at CHEST 2021 show the effect of tezepelumab on peak expiratory flow rates in severe asthma.
CHEST 2021, News
A post-hoc analysis of the VENTURE trial evaluated whether baseline oral corticosteroid dosage affected the efficacy of dupilumab in improving severe asthma outcomes.
The Food and Drug Administration (FDA) has approved Saphnelo (anifrolumab-fnia) for the treatment of adults with moderate to severe systemic lupus erythematosus who are receiving standard therapy. Type I interferons (IFNs) play a role in the pathogenesis of systemic lupus erythematosus (SLE). Anifrolumab-fnia, a human immunoglobulin G1 kappa monoclonal antibody, binds to subunit 1 of…
The American Thoracic Society has released a new clinical practice guideline on the pharmacologic management of chronic obstructive pulmonary disease.
In a study, the calcineurin inhibitor tacrolimus proved to be noninferior to intravenous cyclophosphamide.
Does the allergic status of patients with asthma affect asthma exacerbation rates and outcomes following COVID-19?